{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:05:13Z","timestamp":1777550713278,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Lay Summary<\/jats:title>\n               <jats:p>Higher age (65 years or over), long-term smoking, or a previous cardiovascular event (such as heart attack) should be considered safety risks when considering treatment with tofacitinib versus tumor necrosis factor inhibitors for people with ulcerative colitis.<\/jats:p>","DOI":"10.1093\/crocol\/otae049","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T19:43:02Z","timestamp":1726602182000},"source":"Crossref","is-referenced-by-count":3,"title":["Review: Risk Stratification of Patients With Ulcerative Colitis for Treatment With Tofacitinib"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"first","affiliation":[{"name":"Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University , Milan ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Pan\u00e9s","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Unit, Department of Gastroenterology, Hospital Cl\u00ednic de Barcelona, IDIBAPS, CIBEREHD , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marla","family":"Dubinsky","sequence":"additional","affiliation":[{"name":"Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0490-8350","authenticated-orcid":false,"given":"Xiang","family":"Guo","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Collegeville, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , Oslo ,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University , Kiel ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-4242","authenticated-orcid":false,"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD), Universidad Aut\u00f3noma de Madrid (UAM) , Madrid,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"7","key":"2024100313011916600_CIT0001","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"issue":"18","key":"2024100313011916600_CIT0002","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"2024100313011916600_CIT0003","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2024100313011916600_CIT0004","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2024100313011916600_CIT0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"issue":"7","key":"2024100313011916600_CIT0006","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2024100313011916600_CIT0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2024100313011916600_CIT0008","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/ecco-jcc\/jjad104","article-title":"Major adverse cardiovascular events by baseline cardiovascular risk in patients with ulcerative colitis treated with tofacitinib: data from the OCTAVE clinical programme","volume":"17","author":"Schreiber","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2024100313011916600_CIT0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"GBD Inflammatory Bowel Disease Collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"11","key":"2024100313011916600_CIT0010","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"8","key":"2024100313011916600_CIT0011","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2468-1253(19)30173-6","article-title":"Comorbidities in inflammatory bowel disease: a call for action","volume":"4","author":"Argollo","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"1","key":"2024100313011916600_CIT0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","article-title":"Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)","volume":"73","author":"Dougados","year":"2014","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"2024100313011916600_CIT0013","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2024100313011916600_CIT0014","doi-asserted-by":"crossref","first-page":"otae004","DOI":"10.1093\/crocol\/otae004","article-title":"Association between smoking status and the efficacy and safety of tofacitinib in patients with ulcerative colitis","volume":"6","author":"Rubin","year":"2024","journal-title":"Crohns Colitis 360."},{"issue":"8","key":"2024100313011916600_CIT0015","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"10S","key":"2024100313011916600_CIT0016","doi-asserted-by":"crossref","first-page":"S911","DOI":"10.14309\/01.ajg.0000954416.69032.a8","article-title":"Tofacitinib for the treatment of ulcerative colitis: up to 9.2 years of safety data from the global clinical program [abstract S1194]","volume":"118","author":"Pan\u00e9s","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2024100313011916600_CIT0017","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","article-title":"Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan\u00ae administrative claims database with tofacitinib trial data","volume":"27","author":"Curtis","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"11","key":"2024100313011916600_CIT0018","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing cardiovascular and cancer risk associated with JAK inhibitors","volume":"46","author":"Yang","year":"2023","journal-title":"Drug Saf."},{"issue":"3","key":"2024100313011916600_CIT0019","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3390\/cancers15030871","article-title":"Risk of cancer in patients with inflammatory bowel diseases and keys for patient management","volume":"15","author":"Laredo","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"20","key":"2024100313011916600_CIT0020","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J Gastroenterol."},{"issue":"7","key":"2024100313011916600_CIT0021","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2017-314015","article-title":"Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study","volume":"67","author":"Kirchgesner","year":"2018","journal-title":"Gut."},{"issue":"5","key":"2024100313011916600_CIT0022","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCHEARTFAILURE.114.001152","article-title":"Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish nationwide cohort study","volume":"7","author":"Kristensen","year":"2014","journal-title":"Circ Heart Fail."},{"issue":"8","key":"2024100313011916600_CIT0023","doi-asserted-by":"crossref","first-page":"e0201991","DOI":"10.1371\/journal.pone.0201991","article-title":"Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease","volume":"13","author":"Le Gall","year":"2018","journal-title":"PLoS One."},{"issue":"9715","key":"2024100313011916600_CIT0024","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet."},{"issue":"1","key":"2024100313011916600_CIT0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MEG.0000000000000495","article-title":"Thromboembolism as an important complication of inflammatory bowel disease","volume":"28","author":"Bollen","year":"2016","journal-title":"Eur J Gastroenterol Hepatol."},{"issue":"1","key":"2024100313011916600_CIT0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ibd\/izac084","article-title":"Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program","volume":"29","author":"Lichtenstein","year":"2023","journal-title":"Inflamm Bowel Dis."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otae049\/59199744\/otae049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae049\/59552076\/otae049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/6\/4\/otae049\/59552076\/otae049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T13:01:33Z","timestamp":1727960493000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otae049\/7761935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otae049","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,19]]},"article-number":"otae049"}}